Juan Camilo Arjona Ferreira, Head of R&D and Chief Medical Officer of Organon & Co. (NYSE:OGN), filed a Form 4 on August 12, 2026, reporting the vesting of restricted stock units and a related share withholding transaction dated August 11, 2026.

Key Highlights

  • RSU vesting: 11,519 restricted stock units converted to common stock on August 11, 2026, representing the third and final vesting installment of a three-part grant, at a conversion price of $0.
  • Shares withheld: 4,134 shares of common stock were disposed of on August 11, 2026, at a price of $13.62 per share, coded as an F (tax withholding) transaction.
  • Resulting ownership: Following both transactions, Arjona Ferreira directly beneficially owned 37,432.477 shares of Organon common stock.
  • Derivative securities: The restricted stock unit balance for this grant fell to 0 following the M-coded conversion transaction.
  • Role: The reporting person is identified in the filing as an officer with the title Head of R&D and CMO.

Final RSU Tranche Vests for Organon's Head of R&D

According to the filing, Juan Camilo Arjona Ferreira held restricted stock units that were scheduled to vest in three equal installments. The Form 4 discloses that the third and final installment of 11,519 units vested on August 11, 2026, with each unit representing a contingent right to receive one share of Organon & Co. common stock. The conversion was recorded under transaction code M at a price of $0, bringing the post-conversion balance of this RSU grant to zero.

Immediately following the vesting, the filing records a separate transaction coded F, in which 4,134 shares were disposed of at $13.62 per share. Transaction code F in SEC Form 4 filings denotes shares withheld by the issuer to cover tax obligations upon vesting. After both the M and F transactions, the filing states that Arjona Ferreira directly owned 37,432.477 shares of Organon common stock. The filing was signed by Tarnetta Jones as attorney-in-fact for Dr. Juan Camilo Arjona Ferreira and submitted on August 12, 2026.

The filing does not indicate any open-market purchases or sales of common stock. No Rule 10b5-1 plan box is checked in connection with these transactions, according to the form's face page.

What Was Disclosed

The Form 4 discloses the final vesting of 11,519 restricted stock units into Organon common stock and the simultaneous withholding of 4,134 shares at $13.62 each to satisfy tax obligations, leaving the officer with 37,432.477 directly owned shares.